We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The approval comes after Roche presented results from a Phase III trial, which reduced the risk of breast cancer coming back by half in patients in the Kadcyla group. Read More
The FDA’s cancer drug advisory committee voted Tuesday on two new treatments from Daiichi Sankyo—backing one while giving the thumbs down for the other. Read More
AbbVie has settled its lawsuit with Boehringer Ingelheim, the last domino to fall in an all-out patent war that will protect AbbVie’s mega-blockbuster Humira until 2023. Read More
Merck urged the FDA to look into potential safety concerns as the agency seeks to widen patient eligibility criteria for oncology drug trials of HIV, hepatitis B and hepatitis C patients. Read More